Japan’s Takeda took another bite out of Boston-area biotech this week, while Ernst & Young’s numbers showed just how juicy that apple is. Here’s more on that, and the rest of the week’s life sciences news.
—Not long after its $8.8 billion acquisition of Millennium Pharmaceuticals, Japanese drug giant Takeda Pharmaceutical Company forged an agreement with one of the firm’s Cambridge, MA, neighbors, Alnylam Pharmaceuticals (NASDAQ: ALNY). The deal is potentially worth more than $1 billion over five years.
—Ernst & Young revealed, presumably to nobody’s surprise, that 2007 rocked for New England biotech. Greg summed up the sunny stats.
—In a letter to shareholders, activist investor Carl Icahn once more made the case for his slate of nominees to the Biogen Idec (NASDAQ: BIIB) board, and said if his representatives are elected they’ll do more than agitate for a quick sale of the Cambridge, MA-based biotech.
—Differential Proteomics, a diagnostics startup based in Beverly, MA, took the $10,000 first prize in the 2008 North of Boston Business Plan Competition.
—Atlas Venture of Waltham, MA, placed a bet on the emerging field of mircoRNA by co-leading an $8 million Series A investment in Boulder, CO-based Miragen Therapeutics, which plans to use the approach to develop treatments for heart failure and muscle disease.
—The assets and operations of Meriden, CT-based flu vaccine maker Protein Sciences were bought by Emergent BioSolutions, of Rockville, MD, in a deal worth up to $78 million.
—HyperMed, a medical imaging firm in Burlington, MA, raised $4 million from Greenwich, CT’s GBP Capital.